Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
QuintilesIMS
Teva
Chinese Patent Office
McKesson
Healthtrust
McKinsey
Cipla

Generated: December 9, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SUMATRIPTAN AND NAPROXEN SODIUM

« Back to Dashboard

Clinical Trials for Sumatriptan And Naproxen Sodium

Trial ID Title Status Sponsor Phase Summary
NCT00240617 Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks Completed GlaxoSmithKline Phase 3 The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
NCT00240630 Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks Completed GlaxoSmithKline Phase 3 The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
NCT00329355 Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA) Completed GlaxoSmithKline Phase 3 This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.
NCT00329459 Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea Completed GlaxoSmithKline Phase 3 This study was designed to determine efficacy of TREXIMA compared to placebo for the treatment of a menstrual migraine.
NCT00382993 A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Completed GlaxoSmithKline Phase 3 This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 2 of 2]
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Sumatriptan And Naproxen Sodium

Condition Name

Condition Name for Sumatriptan And Naproxen Sodium
Intervention Trials
Migraine Disorders 15
Migraine 6
Migraine With or Without Aura 2
Migraine Headaches 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Sumatriptan And Naproxen Sodium
Intervention Trials
Migraine Disorders 24
Headache 2
Premenstrual Syndrome 2
Migraine with Aura 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Sumatriptan And Naproxen Sodium

Trials by Country

Trials by Country for Sumatriptan And Naproxen Sodium
Location Trials
United States 284
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Sumatriptan And Naproxen Sodium
Location Trials
Tennessee 13
Texas 12
Ohio 12
Florida 11
California 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Sumatriptan And Naproxen Sodium

Clinical Trial Phase

Clinical Trial Phase for Sumatriptan And Naproxen Sodium
Clinical Trial Phase Trials
Phase 4 5
Phase 3 13
Phase 2/Phase 3 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Sumatriptan And Naproxen Sodium
Clinical Trial Phase Trials
Completed 23
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Sumatriptan And Naproxen Sodium

Sponsor Name

Sponsor Name for Sumatriptan And Naproxen Sodium
Sponsor Trials
GlaxoSmithKline 19
POZEN 2
Johns Hopkins University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Sumatriptan And Naproxen Sodium
Sponsor Trials
Industry 22
Other 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Queensland Health
Deloitte
UBS
Harvard Business School
Cipla
Fish and Richardson
Baxter
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.